International Circulation: In clinical practice， many patients with atrial fibrillation need to be treated with drug conversion or electrical conversion. In order to reduce the risk of thromboembolism， what is the best choice of anticoagulant under drug or electrical conversion therapy?
　　《国际循环》：在临床实践中，很多心房颤动患者需接受药物复律或电复律治疗。为降低血栓栓塞风险，药物或电复律治疗情况下抗凝的最佳选择是什么？
　　Dr. Camm: Your question actually can be answered with some data on this occasion because there has been a direct comparison between warfarin and dabigatran. It is a set of data that emerges from the RE-LY trial where the best part of 1900 patients were subjected to cardioversion and these were equally split (around 600 in each arm of the trial). Therefore we have a direct comparison between warfarin and the two doses of dabigatran. In terms of strokes following cardioversion， these were small in number and more-or-less equally split between warfarin and dabigatran; slightly fewer with the high dose of dabigatran and slightly more with the low dose of dabigatran. So I think we can use dabigatran for cardioversion although we don’t have much data on patients who were started for only a short period of time， for example， three weeks of dabigatran therapy. But the data from RE-LY pertained to patients who had been anticoagulated or treated with dabigatran/warfarin for at least three weeks but many had been treated for longer. There is no reason to assume that three weeks of treatment is not sufficient.
　　Dr. Camm：你的问题实际上可由一些数据来回答，因为华法林与达比加群之间已有直接<